A Phase 1/2a Open-label Study of Sequential Pralatrexate and Gemcitabine With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Lymphoproliferative Malignancies.

Trial Profile

A Phase 1/2a Open-label Study of Sequential Pralatrexate and Gemcitabine With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Lymphoproliferative Malignancies.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Apr 2014

At a glance

  • Drugs Pralatrexate (Primary) ; Folic acid; Gemcitabine; Vitamin B12 analogues
  • Indications B cell lymphoma; Hodgkin's disease; Lymphoproliferative disorders; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 17 Jan 2012 Actual patient number (119) added as reported by ClinicalTrials.gov.
    • 17 Jan 2012 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
    • 17 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top